drug
bivamelagon
Phase 2updated 6mo agoby $RYTM RHYTHM PHARMACEUTICALS, INC.
Phase 2community read0 votes
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
Trials studying bivamelagon
News(2)
- Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZenecaAstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.biospace · 12d ago
- Rhythm doubles down on LG obesity license, raising payout to as much as $855MRhythm Pharmaceuticals and LG Chem have rewritten the terms of their licensing agreement for the oral obesity and hyperphagia drug bivamelagon, growing to $855 million in scheduled payments from th…fiercebiotech · 14d ago
Data sources
last refreshed 43m ago
Found something off?
comments(0)
5-min edit window · permanent after that